ライフサイエンスコーパス: soft tissue sarcoma

1 nerve sheath tumor (MPNST) is an aggressive soft tissue sarcoma.

2 nes, as well as in tumors from patients with soft tissue sarcoma.

3 s trabectedin exhibited efficacy in advanced soft tissue sarcoma.

4 ry subunit of PP2A, is associated with human soft tissue sarcoma.

5 el have activity in patients with metastatic soft tissue sarcoma.

6 ogenesis, we have generated a mouse model of soft tissue sarcoma.

7 epithelial cancer, but not in this model of soft tissue sarcoma.

8 eatment of choice for patients with advanced soft tissue sarcoma.

9 a group of candidate genes and survival with soft tissue sarcoma.

10 ting to potential new therapeutic targets of soft tissue sarcoma.

11 ontrol rate than surgery alone for extremity soft tissue sarcoma.

12 future studies of doxorubicin in metastatic soft tissue sarcoma.

13 ved no prior systemic therapy for metastatic soft tissue sarcoma.

14 n effective treatment strategy for childhood soft tissue sarcoma.

15 18 (41%) had bone sarcoma, and 26 (59%) had soft tissue sarcoma.

16 our institution for a surgical procedure for soft tissue sarcoma.

17 treatment for locally advanced or metastatic soft-tissue sarcoma.

18 newly diagnosed lymphoma, neuroblastoma, or soft-tissue sarcoma.

19 ne treatment for most patients with advanced soft-tissue sarcoma.

20 treatment option for patients with advanced soft-tissue sarcoma.

21 bdomyosarcoma, a highly aggressive pediatric soft-tissue sarcoma.

22 st-line treatment for advanced or metastatic soft-tissue sarcoma.

23 ncer Center, through probands with childhood soft-tissue sarcoma.

24 peripheral nerve sheath tumor, an aggressive soft-tissue sarcoma.

25 ary thyroid carcinoma, and 13% for secondary soft-tissue sarcoma.

26 esting a potential shift in the treatment of soft-tissue sarcoma.

27 lin could be a treatment option for advanced soft-tissue sarcoma.

28 bility of eribulin in advanced or metastatic soft-tissue sarcoma.

29 rcoma metastasis in a primary mouse model of soft-tissue sarcoma.

30 icin in patients with advanced or metastatic soft-tissue sarcoma.

31 llows reliable and accurate local staging of soft-tissue sarcoma.

32 tromal tumors (GISTs) are rare but treatable soft tissue sarcomas.

33 apy on survival has been minimal in advanced soft tissue sarcomas.

34 curative for primary nonmetastatic extremity soft tissue sarcomas.

35 nd may be confused with nonmyogenic, non-RMS soft tissue sarcomas.

36 trated to be more active compared with other soft tissue sarcomas.

37 remains the standard treatment for advanced soft tissue sarcomas.

38 ive chemotherapy for patients with localized soft tissue sarcomas.

39 in tumorigenesis and may aid in diagnosis of soft tissue sarcomas.

40 or types including testicular carcinomas and soft tissue sarcomas.

41 man sarcoma cell lines derived from bone and soft tissue sarcomas.

42 profile and the development of metastasis in soft tissue sarcomas.

43 23 (2.5%) patients who had radiation-induced soft tissue sarcomas.

44 phy (PET) in the management of patients with soft tissue sarcomas.

45 cell proliferation and a worse prognosis in soft tissue sarcomas.

46 better understand the biological behavior of soft tissue sarcomas.

47 on and metastasis of many cancers, including soft tissue sarcomas.

48 S FDA approved for the treatment of advanced soft tissue sarcomas.

49 amous cell carcinomas, mast cell tumors, and soft tissue sarcomas.

50 inical trial involving localized, high-risk, soft tissue sarcomas.

51 val in patients after resection of high-risk soft-tissue sarcomas.

52 efit in T-staging of primary bone tumors and soft-tissue sarcomas.

53 ated efficacy in nonleiomyosarcoma histology soft-tissue sarcomas.

54 might improve the treatment and prognosis of soft-tissue sarcomas.

55 topathologic tumor response in patients with soft-tissue sarcomas.

56 peripheral-nerve tumours, skin cancers, and soft-tissue sarcomas.

57 important for disease control in high-grade soft-tissue sarcomas.

58 xorubicin as first-line therapy for advanced soft-tissue sarcomas.

59 maging for determining treatment response in soft-tissue sarcomas.

60 l proliferation/tumorigenesis in a subset of soft-tissue sarcomas.

61 ant fatty tumors, are the second most common soft-tissue sarcomas.

62 ebo plus cisplatin in patients with advanced soft-tissue sarcomas.

63 ment of tumour vascular-disrupting drugs for soft-tissue sarcomas.

64 ty patients with locally advanced high-grade soft-tissue sarcoma (10 men and 10 women; mean age, 49 +

65 In soft tissue sarcomas, [18F]fluoro-2-deoxy-D-glucose upta

66 arcinoma were breast cancer (5 patients) and soft-tissue sarcoma (2 patients).

67 homa (hazard ratio [95% CI], 3.5 [1.7-7.1]); soft-tissue sarcoma (2.8 [2.1-3.9]); breast carcinoma (2

68 ostoperative surveillance after resection of soft-tissue sarcoma (35 with high-grade sarcoma) were st

69 geted therapies currently in development for soft tissue sarcomas, a better understanding of the mole

70 tients with chemotherapy-refractory bone and soft-tissue sarcomas according to IGF-1R expression by i

71 ging of the primary tumor site for extremity soft tissue sarcomas add little to the detection of recu

72 It represents the most frequent malignant soft tissue sarcoma affecting the pediatric population a

73 olar rhabdomyosarcomas (ARMS) are aggressive soft-tissue sarcomas affecting children and young adults

74 These cells formed invasive soft tissue sarcomas after i.m. injection into nude or s

75 nced, unresectable, or metastatic high-grade soft-tissue sarcoma, age 18-60 years with a WHO performa

76 alyzed 2,084 patients with localized primary soft tissue sarcoma (all anatomic sites) treated from 19

77 Ki-67 proteins were studied in 182 cases of soft tissue sarcomas (American Joint Committee on Cancer

78 rationalizes clinical studies in humans with soft tissue sarcoma, an indication with a notably high u

79 ents aged 18 years and older with metastatic soft-tissue sarcomas, an Eastern Cooperative Oncology Gr

80 orrelated with clinical outcomes in Ewing's, soft tissue sarcomas and gastrointestinal stromal tumor.

81 and number of previous regimens for advanced soft-tissue sarcoma and in blocks of six.

82 tandard of care for patients with metastatic soft-tissue sarcoma and median overall survival for thos

83 ocally advanced, unresectable, or metastatic soft-tissue sarcomas and so this combination cannot be r

84 se was observed in a patient with metastatic soft tissue sarcoma, and 14 patients exhibited disease s

85 lly inhibit growth and angiogenesis of human soft tissue sarcoma, and we explored its capacity to enh

86 were noted, including epithelial carcinomas, soft tissue sarcomas, and hematopoietic tumors.

87 on-Hodgkin lymphoma, acute myeloid leukemia, soft-tissue sarcoma, and central nervous system cancer.

88 fficient details to encompass the variety of soft-tissue sarcomas, and available prognostic methods n

89 en in advanced uterine leiomyosarcoma, other soft-tissue sarcomas, and pediatric sarcomas is discusse

90 Soft tissue sarcomas are a heterogeneous group of tumors

91 Adult soft tissue sarcomas are a heterogeneous group of tumors

92 ing the preoperative management of extremity soft tissue sarcomas are continuing in an attempt to opt

93 Soft tissue sarcomas are mesenchymal tumors that are fat

94 Retroperitoneal soft tissue sarcomas are rare tumors estimated to accoun

95 to 90% of patients with high-grade extremity soft tissue sarcomas are treatable with a limb salvage a

96 Soft-tissue sarcomas are heterogeneous cancers that can

97 in patients with unresectable or metastatic soft-tissue sarcoma at 16 clinical sites in the USA.

98 croscopically resected, Trojani grade II-III soft-tissue sarcomas at any site, no metastases, perform

99 ative incidence for all SCs combined and for soft tissue sarcomas, bone cancers, and melanoma were ca

100 Liposarcomas are the most common type of soft tissue sarcoma but their genetics are poorly define

101 and grading performance of (18)F-FDG PET for soft-tissue sarcoma, but each study has had a limited sa

102 The Soft Tissue Sarcoma Committee of the Children's Oncology

103 ubsets with different outcomes, allowing the Soft Tissue Sarcoma Committee of the Children's Oncology

104 improves survival of patients with advanced soft-tissue sarcoma compared with doxorubicin alone.

105 A multicenter, randomized clinical trial in soft tissue sarcoma comparing gemcitabine alone with thi

106 ts were treated according to the Cooperative Soft Tissue Sarcoma (CWS) trial protocols.

107 entered 10,000 patients into our prospective soft tissue sarcoma database.

108 ard to the management of these patients with soft tissue sarcomas: delays in diagnosis, trial availab

109 habdomyosarcoma, synovial sarcoma, and adult soft tissue sarcomas diagnosed in adolescents and young

110 Approximately 30% of patients with soft-tissue sarcoma die from pulmonary metastases.

111 therapeutic options are needed for bone and soft tissue sarcomas, especially for patients with metas

112 Angiosarcoma (AS) is a rare understudied soft tissue sarcoma exhibiting endothelial cell differen

113 and ifosfamide-which have been used to treat soft-tissue sarcoma for more than 30 years-still have an

114 Genetic aberrations responsible for soft-tissue sarcoma formation in adults are largely unkn

115 Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma found in children and young adults.

116 gradual migration in the local treatment of soft tissue sarcomas from amputation and similar radical

117 Synovial sarcoma is an aggressive soft tissue sarcoma genetically defined by the fusion on

118 17 of 54 patients in the IGF-1R-positive soft-tissue sarcoma group (31%; one-sided 95% CI lower b

119 activated partial thromboplastin time in the soft-tissue sarcoma group (three [7%] each).

120 e additional patients in the IGF-1R-positive soft-tissue sarcoma group (total of 57 patients) and nin

121 the bone sarcoma group and four [10%] in the soft-tissue sarcoma group) had treatment-emergent seriou

122 e of three treatment groups: IGF-1R-positive soft-tissue sarcoma (group A), IGF-1R-positive bone sarc

123 comas (group B), or IGF-1R-negative bone and soft-tissue sarcoma (group C).

124 and host plasminogen cooperate to facilitate soft tissue sarcoma growth and suppress the accumulation

125 Seven (18%) of 40 patients with soft-tissue sarcoma had an objective response, including

126 Patients with soft-tissue sarcoma had to be aged 18 years or older to

127 prognostic role of Skp2 in a large series of soft tissue sarcomas has not been previously investigate

128 treatment for locally advanced or metastatic soft-tissue sarcoma has been doxorubicin.

129 Standard therapy for advanced soft-tissue sarcoma has not changed substantially in dec

130 omyosarcoma (RMS), the most common pediatric soft-tissue sarcoma, has two major histological subtypes

131 Prognostic variables in soft tissue sarcoma have been defined for local recurren

132 Numerous studies on extremity soft tissue sarcomas have consistently shown that presen

133 osensitive tumors compared to other types of soft tissue sarcomas, however, prognosis for advanced re

134 erexpression of MMP-1 and MMP-8 in the human soft tissue sarcoma HSTS26T leads to a significant deple

135 (LMS) is one of the most common subtypes of soft tissue sarcoma in adults and can occur in almost an

136 S/DDLS) account for approximately 13% of all soft tissue sarcoma in adults and cause substantial morb

137 Rhabdomyosarcoma (RMS) is the most frequent soft tissue sarcoma in children that shares many feature

138 eatment of rhabdomyosarcoma, the most common soft tissue sarcoma in children.

139 Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children.

140 provide a new therapeutic approach for human soft tissue sarcoma in the clinic.

141 Rhabdomyosarcoma is the most common soft tissue sarcoma in the pediatric population.

142 can be used to generate multiple subtypes of soft tissue sarcomas in mice.

143 Rhabdomyosarcoma (RMS) is the commonest soft-tissue sarcoma in childhood and is characterized by

144 oping skeletal muscle and is the most common soft-tissue sarcoma in children and adolescents.

145 habdomyosarcomas (RMS) are the most frequent soft-tissue sarcoma in children and characteristically s

146 atic rhabdomyosarcoma (RMS), the most common soft-tissue sarcoma in children, have a very poor clinic

147 Rhabdomyosarcoma (RMS) is the most common soft-tissue sarcoma in children, yet molecular events as

148 skeletal muscle lineage, is the most common soft-tissue sarcoma in children.

149 n, showed clinical activity against advanced soft-tissue sarcoma in phase 1 studies.

150 ival and distant metastases in patients with soft-tissue sarcoma in their extremities.

151 therapy options for patients with metastatic soft-tissue sarcomas in the United States, after a gap o

152 areas in predicting outcome of patients with soft tissue sarcoma include response to neoadjuvant chem

153 also highly unstable in three of eight ALT+ soft tissue sarcomas, indicating that somatic destabiliz

154 oblastomas (IRR = 2.34, 95% CI: 1.21, 4.16), soft-tissue sarcomas (IRR = 2.12, 95% CI: 1.09, 3.79), a

155 survival of patients with primary extremity soft tissue sarcoma is controversial and its effect on i

156 only approved targeted therapy for advanced soft tissue sarcoma is pazopanib.

157 ough the application of HDR brachytherapy to soft tissue sarcoma is relatively new, it seems to resul

158 s with intermediate- to high-grade extremity soft tissue sarcomas is associated with the development

159 Although a subset of soft tissue sarcomas is characterized by simple karyotyp

160 Although the clinical behavior of soft tissue sarcomas is highly variable, few reliable de

161 e role of the Hippo pathway effector YAP1 in soft tissue sarcomas is poorly defined.

162 sential step in the diagnostic evaluation of soft tissue sarcomas is tumor biopsy, functional imaging

163 The role of systemic chemotherapy for soft-tissue sarcoma is still evolving, but at present th

164 igation of aldoxorubicin therapy in advanced soft-tissue sarcoma is warranted.

165 cy to be marketed for advanced or metastatic soft tissue sarcoma) is being explored.

166 g from mesenchymal tissues, such as bone and soft-tissues sarcomas, is still largely unclear.

167 ologic variation which is especially true in soft tissue sarcomas, it can predict tumor grade, and it

168 for adolescent and young adult patients with soft tissue sarcomas lag behind those of children diagno

169 on (R0, R1) of abdominal and retroperitoneal soft-tissue sarcomas (median diameter 10 cm, G2 48.3%, G

170 his review addresses PET/MRI of bone tumors, soft-tissue sarcoma, melanoma, and lymphoma.

171 b with doxorubicin in patients with advanced soft-tissue sarcoma met its predefined primary endpoint

172 ee, and overall survival among patients with soft-tissue sarcoma, most of whom had received at least

173 diagnosis of locally advanced or metastatic soft-tissue sarcoma not previously treated with an anthr

174 Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma of childhood and adolescence.

175 Rhabdomyosarcoma is the most common soft tissue sarcoma of childhood and adolescence.

176 omyosarcoma (ARMS) is one of the most common soft tissue sarcoma of childhood, yet the outcome for th

177 l muscle differentiation, is the most common soft tissue sarcoma of childhood.

178 Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma of skeletal muscle origin in childre

179 chymally transformed breast cancer cells and soft tissue sarcomas of diverse histological subtypes.

180 ients with localized, potentially resectable soft tissue sarcomas of the extremities or body wall.

181 Guided Preoperative Radiotherapy for Primary Soft Tissue Sarcomas of the Extremity) study are appropr

182 Rhabdomyosarcoma (RMS) is a common soft-tissue sarcoma of childhood in need of more effecti

183 ases in patients after surgical resection of soft-tissue sarcoma of the extremities.

184 produce excellent results, such as bone and soft-tissue sarcoma of the skull base, head and neck, an

185 lly confirmed locally advanced or metastatic soft-tissue sarcoma of Trojani grade 2 or 3, disease pro

186 Angiosarcomas are rare soft-tissue sarcomas of endothelial cell origin that hav

187 is of an advanced unresectable or metastatic soft-tissue sarcoma, of intermediate or high grade, for

188 t among survivors of CNS tumors and bone and soft tissue sarcomas on strength testing (score +/- SD:

189 el, phase 2 study, we enrolled patients with soft-tissue sarcoma or bone sarcoma from 12 academic cen

190 afety and activity in patients with advanced soft-tissue sarcoma or bone sarcoma.

191 dgkin lymphoma, kidney tumor, neuroblastoma, soft-tissue sarcoma, or malignant bone tumor before the

192 For soft tissue sarcomas, patient education and office visit

193 a defective p53 response, we found that male soft tissue sarcoma patients carrying the minor T allele

194 Several phase II trials in advanced soft tissue sarcoma patients have investigated the effic

195 vide modest benefit overall to nonadipocytic soft tissue sarcoma patients, but we have yet to identif

196 We present data from a pilot study in 10 soft-tissue sarcoma patients imaged with (11)C-thymidine

197 In soft-tissue sarcoma patients, we find that the alleles o

198 e of histologic type in radiation-associated soft tissue sarcomas (RASs) and determine whether RASs a

199 total of 53 patients with advanced non-GIST soft tissue sarcomas received sunitinib 37.5 mg daily.

200 sion-free survival of patients with advanced soft tissue sarcoma receiving either regimen of standard

201 has recently been approved for nonadipocytic soft tissue sarcomas refractory to chemotherapy.

202 juvant chemotherapy on survival for resected soft-tissue sarcoma remains unknown.

203 Soft tissue sarcomas represent a diverse group of tumors

204 ti-platform molecular landscape of 206 adult soft tissue sarcomas representing 6 major types.

205 hat the Hippo pathway is deregulated in many soft-tissue sarcomas, resulting in elevated expression o

206 the conventional staging of retroperitoneal soft tissue sarcomas (RPS) is essential in providing eff

207 mated to account for 15%of all patients with soft tissue sarcoma seen in referral populations.

208 o investigate the genetic basis for bone and soft-tissue sarcoma seen in routine clinical practice.

209 with doxorubicin and ifosfamide in resected soft-tissue sarcoma showed no benefit in relapse-free su

210 cer (SIR 13.3), brain tumors (SIR 10.1), and soft tissue sarcoma (SIR 9.1).

211 and neck carcinoma occurred in survivors of soft tissue sarcoma (SIR = 22.6), neuroblastoma (SIR = 2

212 est following neuroblastoma (SIR = 24.2) and soft tissue sarcoma (SIR = 6.2).

213 renal cancer (SIR, 3.9; 95% CI, 2.0 to 7.5), soft tissue sarcoma (SIR, 2.6; 95% CI, 1.5 to 4.4), and

214 However, for 4 deaths of soft tissue sarcoma (SMR = 4.1, 95% CI: 1.1, 10.5), the

215 We applied this approach to 52 childhood soft tissue sarcoma specimens in an attempt to identify

216 and poly(ADP-ribose) polymerase cleavage in soft tissue sarcoma (STS) cells.

217 American Joint Committee on Cancer stage III soft tissue sarcoma (STS) have high risks of distant rec

218 Randomized controlled trials (RCTs) in soft tissue sarcoma (STS) have used varying end points.

219 a (MFH) has been regarded as the most common soft tissue sarcoma (STS) in adults.

220 n combination chemotherapy for patients with soft tissue sarcoma (STS) is unclear.

221 to guide the multidisciplinary management of soft tissue sarcoma (STS) of the extremities, controvers

222 radiation therapy (IMRT) in the treatment of soft tissue sarcoma (STS) of the extremity is increasing

223 ve local control in patients with high-grade soft tissue sarcoma (STS) of the extremity.

224 din-mimetic mechanism, suggested activity in soft tissue sarcoma (STS) patients.

225 he American Joint Committee on Cancer (AJCC) soft tissue sarcoma (STS) staging system is more accurat

226 therapy in patients with first-line advanced soft tissue sarcoma (STS) to assess progression-free sur

227 s late toxicities in patients with extremity soft tissue sarcoma (STS) treated with preoperative imag

228 n (9-NC) in patients with advanced chordoma, soft tissue sarcoma (STS), and gastrointestinal stromal

229 Here, in a study of 18 canine patients with soft tissue sarcoma (STS), CIVO captured complex, patien

230 lung, such as renal cell carcinoma (RCC) and soft tissue sarcoma (STS), have an inherent capacity to

231 is tumor displays characteristic features of soft tissue sarcoma (STS), including deep soft tissue pr

232 whether survival of patients with extremity soft tissue sarcoma (STS), stratified for known risk fac

233 Using a murine model of soft tissue sarcoma (STS), we show that disruption of th

234 ngs progression-free survival in adults with soft tissue sarcoma (STS).

235 ant chemotherapy (CT) in high-risk extremity soft tissue sarcoma (STS).

236 ns for children with high-risk nonmetastatic soft tissue sarcoma (STS).

237 The AKT signaling pathway is activated in soft tissue sarcoma (STS).

238 f surgical center case volume on outcome for soft tissue sarcoma (STS).

239 nly overexpressed in human tumors, including soft tissue sarcoma (STS).

240 d trabectedin are considered active drugs in soft tissue sarcoma (STS).

241 Soft tissue sarcomas (STS) have a strong propensity for

242 nocortical carcinomas (ACC), CNS tumors, and soft tissue sarcomas (STS) observed in 30%, 27%, 26%, an

243 in and pathogenesis of the majority of adult soft tissue sarcomas (STS) remains poorly understood.

244 currence rates for selected patients with T1 soft tissue sarcomas (STS) treated by surgery alone.

245 In soft tissue sarcomas (STS), low intratumoural O2 (hypoxi

246 ET and CT response criteria in patients with soft-tissue sarcoma (STS) after combined chemotherapy pl

247 to determine if such concern is warranted in soft-tissue sarcoma (STS) of the extremity.

248 Some patients with soft-tissue sarcoma (STS) report a history of injury at

249 Prognosis in soft-tissue sarcoma (STS), the aggressive malignancies o

250 Unresectable metastatic bone sarcoma and soft-tissue sarcomas (STS) are incurable due to the inab

251 Human soft-tissue sarcomas (STS) are rare mesenchymal tumors w

252 Soft-tissue sarcomas (STS) are relatively uncommon, espe

253 the activity of BMS-247550 in patients with soft tissue sarcomas (STSs) who had not received prior c

254 an inferior prognosis compared with sporadic soft tissue sarcomas (STSs).

255 ally engineered autochthonous mouse model of soft-tissue sarcomas (STSs) to determine NG2/CSPG4's rol

256 In 2005, the European Pediatric Soft Tissue Sarcoma Study Group (EpSSG) proposed a conse

257 Genomic profiling of soft tissue sarcomas subtypes reveals a propensity for t

258 ion reduced tumor burden in a mouse model of soft-tissue sarcoma, suggesting that p53 strongly inhibi

259 r inhibitor in the progression of the murine soft tissue sarcoma, T241 were investigated.

260 Synovial sarcoma, a soft tissue sarcoma that develops in adults, is patholog

261 Liposarcoma is a type of soft tissue sarcoma that exhibits poor survival and a hi

262 e in a genetically engineered mouse model of soft tissue sarcoma that loss of GCN2 has no effect on t

263 peripheral nerve sheath tumors (MPNSTs) are soft tissue sarcomas that arise in connective tissue sur

264 ve sheath tumors (MPNST) are highly invasive soft tissue sarcomas that arise within the peripheral ne

265 LOH analysis of 160 cases of RMS and non-RMS soft tissue sarcomas that is at variance with convention

266 of care for adults who have the subtypes of soft tissue sarcomas that typically occur in pediatric p

267 Synovial sarcoma (SS) is an aggressive soft-tissue sarcoma that is often discovered during adol

268 habdomyosarcomas (ARMS) are highly malignant soft-tissue sarcomas that arise in children, adolescents

269 NSTs) represent a group of highly aggressive soft-tissue sarcomas that may occur sporadically, in ass

270 With the exception of soft tissue sarcoma, the authors found little evidence o

271 ine the factors predictive of recurrence for soft tissue sarcomas, the role of salvage therapy, and t

272 At present for soft-tissue sarcomas, the 5-y survival is approximately

273 In rhabdomyosarcoma (RMS), a pediatric soft-tissue sarcoma thought to arise from myogenic precu

274 py should be considered in the management of soft tissue sarcoma to increase local control.

275 ologic response of osteosarcoma, Ewing's and soft tissue sarcomas to chemotherapy, and has correlated

276 t clinical benefit in patients with advanced soft-tissue sarcomas to support its use as a therapeutic

277 toperative Radiotherapy in Curable Extremity Soft Tissue Sarcoma) trial receiving preoperative radiat

278 in and ifosfamide for palliation of advanced soft-tissue sarcoma unless the specific goal is tumour s

279 Although representing only 1% to 2% of soft tissue sarcomas, vascular sarcomas provide unique i

280 clinical outcome of patients with metastatic soft tissue sarcomas, we compared a fixed dose rate infu

281 Subcutaneous soft tissue sarcomas were labeled with the highest fluor

282 95% CI, 1.23 to 7.16), but risks for bone or soft tissue sarcomas were not elevated.

283 ive radiotherapy for patients with extremity soft tissue sarcomas were recently presented at the 2004

284 s with intermediate- to high-grade extremity soft tissue sarcomas were treated at UCLA.

285 cally resectable intermediate- or high-grade soft tissue sarcomas were treated.

286 istologically confirmed diagnosis of bone or soft-tissue sarcoma were allocated on the basis of IGF-1

287 Preoperative MR images in 174 patients with soft-tissue sarcoma were analyzed by two readers.

288 ocally advanced, unresectable, or metastatic soft-tissue sarcoma were screened.

289 ine different histological subtypes of adult soft tissue sarcoma, were examined using the Affymetrix

290 f synovial sarcomas as compared to the other soft tissue sarcomas, which included variably high expre

291 Soft-tissue sarcomas, which result in approximately 10,7

292 - (null) mice developed T-cell lymphomas and soft-tissue sarcomas, while p27-/- mice developed adenom

293 us tissue damage, in patients with extremity soft tissue sarcomas who receive once-daily preoperative

294 ival in patients with advanced or metastatic soft-tissue sarcoma who received eribulin with that in p

295 CI, 19.3 to 31.0]) and survivors of bone and soft-tissue sarcoma who were not treated with chest radi

296 ascertained through patients with childhood soft-tissue sarcoma who were treated at the University o

297 MR imaging examinations in 23 patients with soft-tissue sarcomas who had undergone neoadjuvant thera

298 d-cell tumors (DSRCT), a rare but aggressive soft tissue sarcoma with a high rate of mortality.

299 Rhabdomyosarcoma is a soft-tissue sarcoma with molecular and cellular features

300 e proposed that gene expression profiling in soft tissue sarcoma would identify a genomic-based class